Indeed, although visual criteria did not include the MTL for defining moderate positivity, quantitative tau staging based on the MTL ROI successfully captured differences in biomarker levels and cognitive trajectories between early stages (A+/T− vs. A+/Tmod+), highlighting the relevance of MTL tau deposition as an indicator of initial AD pathology. This evidence concerns the gene TMOD1 and Alzheimer disease.